Peptide Blog
Articles, dosing guides, and expert insights on peptides and their real-world applications.
Retatrutide Beat Ozempic Head to Head: TRANSCEND-T2D-2 Results
TRANSCEND-T2D-2 results: retatrutide cut weight 20.9% vs 9.4% on Ozempic 2 mg and lowered A1C more in type 2 diabetes. Side effects, who quit, and the trial's limits.
HHS Peptide Policy: The 6 Peptides Pharmacies Can Compound and the 10 Rules (2026)
HHS peptide policy explained: the 6 peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax), allowed routes, 10 pharmacy conditions, what is excluded and when.
Eli Lilly Retatrutide Early Access: Who Qualifies and How (2026)
Eli Lilly retatrutide early access is real but narrow: BMI 35+, top-dose failure, 2+ serious complications. Exact criteria, how doctors apply, cost, odds.
Retatrutide TRIUMPH-2 Results: 20.8% Weight Loss in Type 2 Diabetes
Full retatrutide TRIUMPH-2 results from The Lancet: up to 20.8% weight loss and a 1.6-point A1C drop in type 2 diabetes, side effects by dose, and what comes next.
PEPTIDES for Veterans Act: What the VA Peptide Bill Actually Does (2026)
Rep. Nancy Mace introduced the PEPTIDES for Veterans Act on September 1, 2026, ordering the VA to study peptide therapies and run a voluntary pilot. What the bill does, what the evidence shows, and what veterans can legally access today.
GLP-1 Microdosing Statistics 2026: Usage, Doses, Costs & Outcomes (Updated September)
The GLP-1 microdosing statistics that have a source behind them: how many Americans use GLP-1s, what the small trial doses actually did, side effects and dropout by dose, compounding enforcement, prices, and what PeptideDeck readers ask. Every number linked. Updated monthly.
Reader discount
99%+ purity research peptides — third-party tested, COA included
Save 50% with code PEPTIDEDECK
BPC-157 Statistics 2026: Trials, FDA Status, Usage & Prices (Updated September)
60+ sourced BPC-157 statistics for 2026: the 8-6-1 FDA advisory vote, every registered human trial, 232 PubMed papers, search interest, vendor prices, and what PeptideDeck's own readers ask. Every number links to its source. Updated monthly.
CagriSema vs Retatrutide: Which Wins on Weight Loss in 2026?
CagriSema vs retatrutide in 2026: 22.7% vs 28.3% weight loss, why the two phase 3 trials are not comparable, and the tirzepatide bridge that settles it.
Best Peptide Affiliate Program 2026: 10 Peptides Affiliate Programs Compared
Best peptide affiliate program for 2026: ten peptides affiliate programs compared on commission, cookie, payout speed and recurring pay, with real earnings scenarios and how to negotiate up.
Minoxidil for Women: 2% vs 5%, Results Timeline & Side Effects
Minoxidil for women: which strength is FDA-approved, how long results take, the shedding phase explained, side effects, and what happens when you stop.